The new market report analyzes the chronic obstructive pulmonary disease (COPD) therapeutics market in Asia Pacific and discusses recently launched COPD products and approved novel drugs that will complement current market leaders and offer better therapeutic alternatives. The report predicts the growth of the COPD market in five Asia Pacific countries namely, India, China, Australia, South Korea, and Japan.
The report – titled ‘COPD Therapeutics in Asia-Pacific Markets To 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies’ – estimates that the Asia Pacific COPD therapeutics market will grow at a CAGR of 10.2%, from its initial value of US$3.7 billion in 2015 to US$7.3 billion in 2022. The report further mentions various drivers and barriers that will influence the market over the forecast period.
Chronic obstructive pulmonary disease (COPD) affects not only the geriatric population, but a large section of the society due to excessive smoking. Many are known to suffer from this disease for years, and die of it or its complications, thereby increasing the burden economically and socially. The COPD burden is expected to grow in the coming years, industry experts predict.
Due to an increase in the number of smokers around the world, the disease will continue to be a major health concern for a long period. The demand for COPD therapeutics is set to prosper with the given number of people suffering from COPD. Wide range of treatments are available in the market such as bronchodilator monotherapies, bronchodilator and ICS combinations, bronchodilator combinations, and PDE-4 inhibitors. The launch of new products and the approval of novel drugs are fueling market growth. The market is set to go through a transitional phase, with more focus towards triple and targeted combination drug treatments.
Bronchodilators and ICS lead the COPD market; however, they still lack safety and efficiency. The treatments currently available are managing the occurrence and severity of the symptoms, but none of them have shown any long-term disease progression. The focus is now on drugs under development, so as to meet the unmet needs of the COPD therapeutics market.
Japan is a key contributor towards the growth of the Asia Pacific COPD therapeutics market. The growth of the market in this country can be attributed to the emergence of novel therapies. The rate of technological and medical developments and government initiatives to improve lifestyle are a few factors driving the market.
Advinus Therapeutics Ltd, AlgiPharma AS, Allinky Biopharma, Alteogen Inc., Amakem NV, Ampio Pharmaceuticals, Inc., Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Aridis Pharmaceuticals LLC, Achillion Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Axikin Pharmaceuticals, Inc., Bayer AG, Beech Tree Labs, Inc., Bioneer Corporation, Adamis Pharmaceuticals Corporation, and Biotie Therapies Corp. are some of the key players in the COPD therapeutics market in Asia Pacific.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org